BELITE BIO, INC (BLTE)
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical trials, LBS-008 is engineered to modulate vitamin A delivery to the eye, thus preventing the accumulation of detrimental vitamin A metabolites in ocular tissues. Furthermore, Belite Bio is advancing LBS-009, an oral anti-retinol binding protein 4 therapy, through preclinical development. This therapy targets various liver ailments, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Founded in 2016, Belite Bio, Inc. is headquartered in San Diego, California, and operates as a subsidiary of Lin Bioscience International Ltd.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Belite Bio, Inc
NASDAQ:BLTEHealthcare · Biotechnology
+2.97%$154.74
AH$154.74+0.00%vs close
Mkt Cap$6.23B
Float22.63M
O/S40.27M
Vol
$ Vol
RVOL
Inst Own23.5%
SI5.6%
Earnings
Dilution
Financials Summary
Revenue$0
Net Income-$77.61M
Total Assets$780.56M
Free Cash Flow-$37.17M
Debt & Equity
Debt 0%
Equity 100%
Total Debt$429K
Total Equity$770.49M
Shares Outstanding
Short Interest
Split History
No splits on record
Nothing in BLTE's public trading history: no forward or reverse split has affected the share count.
Balance Sheet Details
Assets$780.56M
Liabilities$10.07M
Accounts Receivable$718K
Accounts Payable$0
Inventory$0
PP&E (Net)$777K
Goodwill$0
Intangible Assets$4.92M
Income Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | - | - | - | - | - | - |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross Margin | - | - | - | - | - | - |
| Research and Development | $45.38M | $29.94M | $24.84M | $8.87M | $7.42M | $3.69M |
| Selling, General, and Administrative | $38.83M | $10.06M | $6.82M | $3.95M | $2.38M | $2.06M |
| Other | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Operating Expenses | $84.21M | $40M | $31.67M | $12.82M | $9.8M | $5.74M |
| Operating Income (EBIT) | -$84.21M | -$40M | -$31.67M | -$12.82M | -$9.8M | -$5.74M |
| Operating Margin | - | - | - | - | - | - |
| Interest Expense | $0 | $20K | $25K | $16K | $0 | $21K |
| Interest Income | $0 | $3.74M | $74K | $23K | $5K | $12K |
| Other Income (Expense) | $6.6M | $3.86M | $45K | $173K | $131K | -$9K |
| Income Before Tax (EBT) | -$77.61M | -$36.14M | -$31.62M | -$12.65M | -$9.67M | -$5.75M |
| Income Tax Expense | $0 | $6K | $9K | $0 | $0 | $1K |
| Net Income | -$77.61M | -$36.14M | -$31.63M | -$12.65M | -$9.67M | -$5.75M |
| Net Income Margin | - | - | - | - | - | - |
| Supplementary Data | ||||||
| EPS | -2.31 | -1.18 | -1.19 | -0.63 | -0.40 | -0.62 |
| Diluted EPS | -2.31 | -1.18 | -1.19 | -0.63 | -0.40 | -0.62 |
| Weighted Average OS | 33.54M | 30.54M | 26.59M | 19.98M | 24.10M | 9.21M |
| EBITDA | -$77.15M | -$35.67M | -$31.2M | -$12.43M | -$9.64M | -$5.73M |
| EBITDA Margin | - | - | - | - | - | - |
Balance Sheet
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Assets | ||||||
| Current Assets | ||||||
| Cash and Cash Equivalents | $352.93M | $31.68M | $88.16M | $42.09M | $17.34M | $25.62M |
| Short-Term Investments | $139.49M | $113.47M | $0 | $0 | $0 | $0 |
| Cash and Short-Term Investments | $492.42M | $145.15M | $88.16M | $42.09M | $17.34M | $25.62M |
| Accounts Receivable | $718K | $594K | $867K | $19K | $23K | $40K |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Current Assets | $5K | $0 | $0 | $0 | $0 | $0 |
| Total Current Assets | $494.27M | $147.07M | $89.94M | $42.81M | $17.43M | $25.67M |
| Long-Term Assets | ||||||
| Property, Plant & Equipment Net | $777K | $965K | $1.3M | $1.35M | $94K | $66K |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $0 |
| Intangible Assets | $4.92M | $3.99M | $3.3M | $31K | $0 | $0 |
| Long-Term Investments | $280.17M | $0 | $0 | $0 | $0 | $0 |
| Deferred Tax Assets | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Assets | $425K | $103K | $104K | $88K | $823K | $7K |
| Total Long-Term Assets | $286.28M | $5.06M | $4.7M | $1.47M | $917K | $73K |
| Other Assets | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Assets | $780.56M | $152.13M | $94.64M | $44.27M | $18.35M | $25.74M |
| Liabilities | ||||||
| Current Liabilities | ||||||
| Accounts Payable | $0 | $0 | $0 | $0 | $0 | $0 |
| Short-Term Debt | $0 | $0 | $0 | $0 | $0 | $0 |
| Current Income Tax Payable | $0 | $0 | $0 | $0 | $0 | $0 |
| Current Unearned Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Current Liabilities | $2.21M | $992K | $876K | $456K | $24K | $5K |
| Total Current Liabilities | $9.88M | $6.05M | $3.63M | $2.1M | $1.64M | $972K |
| Long-Term Liabilities | ||||||
| Long-Term Debt | $0 | $0 | $0 | $0 | $31.81M | $31.81M |
| Long-Term Unearned Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Liabilities | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Long-Term Liabilities | $188K | $261K | $578K | $668K | $31.81M | $31.81M |
| Other Liabilities | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $10.07M | $6.31M | $4.21M | $2.77M | $33.44M | $32.78M |
| Stockholders' Equity | ||||||
| Preferred Stock | $0 | $0 | $0 | $0 | $0 | $0 |
| Common Stock | $4K | $3K | $3K | $3K | $1K | $1K |
| Retained Earnings | -$185.26M | -$107.65M | -$71.5M | -$39.87M | -$27.22M | -$17.56M |
| Comprehensive Income & Other | -$536K | -$660K | -$374K | -$392K | -$196K | -$44K |
| Other Stockholders' Equity | $955.74M | $253.47M | $161.93M | $81.37M | $12.13M | $10.52M |
| Total Equity | $770.49M | $145.82M | $90.43M | $41.5M | -$15.09M | -$7.04M |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities and Equity | $780.56M | $152.13M | $94.64M | $44.27M | $18.35M | $25.74M |
| Supplementary Data | ||||||
| Total Debt | $429K | $537K | $886K | $866K | $31.81M | $31.81M |
| Net Debt | -$352.5M | -$31.14M | -$87.27M | -$41.22M | $14.46M | $6.19M |
Cash Flow Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Operating Activities | ||||||
| Net Income | -$77.61M | -$36.14M | -$31.63M | -$12.65M | -$9.67M | -$5.75M |
| Depreciation & Amortization | $464K | $449K | $399K | $198K | $30K | $17K |
| Deferred Income Tax | $0 | $0 | -$4.69M | -$1.91M | $0 | $0 |
| Stock-Based Compensation | $38.92M | $8.99M | $3.82M | $1.48M | $1.53M | $1.36M |
| Changes in Working Capital: | ||||||
| Accounts Receivable | -$66K | $74K | -$72K | -$32K | $0 | $4K |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 |
| Accounts Payable | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Working Capital | $2.62M | $1.06M | -$2.35M | -$459K | $640K | -$73K |
| Total Working Capital Change | $2.55M | $1.13M | -$2.43M | -$491K | $640K | -$69K |
| Other Non-Cash Items | -$1.31M | -$3.66M | $4.69M | $1.91M | -$8K | $0 |
| Net Cash from Operating | -$36.99M | -$29.23M | -$29.84M | -$11.46M | -$7.47M | -$4.44M |
| Investing Activities | ||||||
| Capital Expenditures | -$178K | -$116K | -$63K | -$394K | -$74K | -$20K |
| Acquisitions | $0 | $0 | $0 | $0 | $18K | $0 |
| Purchases of Investments | -$451.99M | -$188.26M | $0 | $0 | $0 | $0 |
| Sales of Investments | $147.06M | $77.84M | $0 | $0 | $0 | $0 |
| Other Investing Activities | $0 | -$35K | $0 | $0 | $0 | $0 |
| Net Cash from Investing | -$305.11M | -$110.57M | -$63K | -$394K | -$56K | -$20K |
| Financing Activities | ||||||
| Debt Repaid | - | - | - | - | - | $2.32M |
| Common Stock Issuance | $292.86M | $42.24M | $77.19M | $37.99M | -$583K | $500K |
| Common Stock Repurchases | $0 | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Financing Activities | $370.37M | $41.36M | -$1.23M | -$1.03M | $0 | $86K |
| Net Cash from Financing | $663.23M | $83.59M | $75.96M | $36.96M | -$583K | $28.06M |
| Forex Effect | $117K | -$269K | $9K | -$366K | -$161K | $4K |
| Net Change in Cash | $321.25M | -$56.48M | $46.07M | $24.75M | -$8.27M | $23.6M |
| Supplementary Data | ||||||
| Operating Cash Flow | -$36.99M | -$29.23M | -$29.84M | -$11.46M | -$7.47M | -$4.44M |
| Capital Expenditure | -$178K | -$151K | -$63K | -$394K | -$74K | -$20K |
| Free Cash Flow | -$37.17M | -$29.39M | -$29.9M | -$11.85M | -$7.55M | -$4.46M |
| Cash at Beginning | $31.68M | $88.16M | $42.09M | $17.34M | $25.62M | $2.02M |
| Cash at End | $352.93M | $31.68M | $88.16M | $42.09M | $17.34M | $25.62M |